Skip to main content
Xellia

In the pipeline

Building the next generation of therapies: advancing what’s essential.
Products are under development.

Anidulafungin

Under development

Apixaban

Under development
For development and marketing authorization studies only

Dabigatran

Under development

Dalbavancin

US DMF submitted

Dalbavancin Vials

Under registration in Europe

Darolutamide

Under development

For development and marketing authorization studies only

Fidaxomicin

For development and marketing authorization studies only

Nystatin

Under development

Rifaximin

Under development

For development and marketing authorization studies only

Rimegepant

Under development

For development and marketing authorization studies only

Teicoplanin

Under development

Ticagrelor

Under development

Interested? Let's talk!

Have a conversation with our sales team to find out more.

Optional